Marinus Pharmaceuticals 2024 Corporate Presentation

Marinus Pharmaceuticals presents its ganaxolone development pipeline for seizure disorder treatments, including FDA-approved ZTALMY and ongoing clinical trials for CDKL5 deficiency disorder, refractory status epilepticus, and Lennox-Gastaut syndrome. The presentation outlines anticipated regulatory milestones, commercialization plans, and the mechanism of action for ganaxolone as a GABAA receptor modulator.